Phase 4Status unknown

Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin (Cor16)

An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin

Sponsor
D16 Pharma & Biotec Ltd. (Industry)
Enrollment
2,000 planned
Conditions
Dyslipidemia
Interventions
Rosuvastatin 5 mg; Rosuvastatin 10 mg
Ages
adults, older adults
Registry
NCT01613729

Full record on ClinicalTrials.gov

From the registry

The primary objective of the study is to compare the efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of \<100 mg/dL after 12 weeks of therapy.

Primary outcomes

  • Efficacy of Rosuvastatin 5 mg once daily with Rosuvastatin 10 mg once daily by assessment of the number of patients with hypercholesterolemia reaching the LDL-C target goal of <100 mg/dL after 12 weeks of therapy.

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered